Portable Ganetespib, Hsp90 Inhibitor (tbi4474) + Free Bonus [3YzofFe9]

Ganetespib: HSP90 Inhibitor for Advanced Therapies

Introducing Ganetespib, a potent HSP90 inhibitor designed for advanced therapeutic applications. This innovative compound boasts a unique molecular structure, formally known as 3-(2,4-Dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one, and is also recognized under the alternate name STA-9090. Ganetespib's key feature lies in its ability to bind to the N-terminal ATP site of heat shock protein 90 (HSP90), effectively inhibiting its function. This action leads to potent cytotoxicity against a wide range of transformed cell lines, making it a promising candidate for the treatment of hematologic and solid tumors.

• Highly effective against 57 transformed cell lines
• Enhances T-cell-mediated killing of melanoma cells

Product Specifications and Formulation

Ganetespib is formulated as a high-purity powder, ensuring a minimum purity of >98%. Its molecular formula is C₂₀H₂₀N₄O₃, with a formula weight of 364.40 g/mol. This inhibitor is highly soluble in DMSO, with a concentration of up to at least 25 mg/ml, making it convenient for researchers and clinicians to use. The product is stable when stored at -20°C and maintains its integrity for over a year.

• Minimum purity of >98%
• Soluble in DMSO (up to 25 mg/ml)
• Storage temperature: -20°C

Applications and Benefits

Ganetespib's versatile nature makes it suitable for a variety of applications in the field of oncology. Its potent cytotoxic effects, combined with its ability to enhance immune responses, make it a valuable tool in clinical trials for various cancers. By upregulating interferon response genes, Ganetespib potentiates responses to anti-CTLA4 and anti-PD1 therapies, offering new hope for patients with melanoma and other solid tumors. Whether used in research or clinical settings, Ganetespib is poised to make a significant impact in the fight against cancer.

• Effective against hematologic and solid tumors
• Potentiation of immune responses
• Use in clinical trials for various cancers